Amgenvs.United Therapeutics
AMGN vs UTHR · both in Biotech & innovation, part of the Medicine, pharma & life science value chain: Innovation-driven biotech companies focused on novel treatment modalities.
Amgen is about 8.5× larger than United Therapeutics by market cap; United Therapeutics trades at the lower P/E (18.0 vs 25.1).
Side by side
| AMGN | UTHR | |
|---|---|---|
| Market cap | $196B | $23.2B |
| Price | $363.39 | $547.06 |
| Today | −0.1% | −1.0% |
| Return YTD | +11.0% | +12.3% |
| Return 1Y | +21.0% | +82.3% |
| P/E | 25.1 | 18.0 |
| P/S | 5.3 | 7.3 |
| P/B | 21.3 | 3.9 |
Data as of 2026-07-11 · updates daily after U.S. close
The two companies
AmgenAMGN
Veteran American biotech with a broad portfolio in oncology, immunology and bone diseases — and an obesity candidate (MariTide) in the pipeline.
Full AMGN profile →United TherapeuticsUTHR
Biopharma in pulmonary hypertension and organ manufacturing (xenotransplantation).
Full UTHR profile →More comparisons in Biotech & innovation
See where AMGN and UTHR sit in the full Medicine, pharma & life science map — every segment from suppliers to end markets.Open the Life science value chain →